Apellis Pharmaceuticals, Inc. (APLS)

Market Cap	5.20B +71.4%
Revenue (ttm)	1.00B +28.5%
Net Income	22.39M
EPS	0.17
Shares Out	127.84M
PE Ratio	236.01
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,081,600
Open	40.61
Previous Close	40.63
Day's Range	40.60 - 40.77
52-Week Range	16.10 - 40.77
Beta	-0.20
Analysts	Hold
Price Target	32.71 (-19.53%)
Earnings Date	May 6, 2026

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glome...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 9, 2017
• Employees: 739
• Stock Exchange: NASDAQ
• Ticker Symbol: APLS
• Website: https://apellis.com

Analyst Summary

According to 21 analysts, the average rating for APLS stock is "Hold." The 12-month stock price target is $32.71, which is a decrease of -19.53% from the latest price.

Price Target

$32.71

(-19.53% downside)

Analyst Consensus: Hold